Anja Zeretzke

Not all anti‐ CD38 antibodies are created equal: The epitope of felzartamab is partially DTT ‐resistant

OBJECTIVES: To evaluate anti-CD38 antibody candidates for their ability to bind to DTT-treated CD38 and red blood cells (RBCs). BACKGROUND: Dithiothreitol (DTT) treatment of RBCs is routinely used to denature CD38 and mitigate interference from anti-CD38 antibodies, such as darat...